RecruitingPHASE1, PHASE2NCT06106672
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
- Principal Investigator
- Roy First, MD, MDCOUR Pharmaceutical
- Intervention
- CNP-106(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (17)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Neuromuscular Clinic and Research Center, Phoenix, Arizona, United States
- Infusion for Health, Brea, California, United States
- University of California, Irvine, Orange, California, United States
- Yale University, New Haven, Connecticut, United States
- Atlantis Research, Miami, Florida, United States
- Quantix Research, LLC, Miami, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Insight Hospital and Medical Center, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Insight Research Institute, Dearborn, Dearborn, Michigan, United States
- University of Missouri, NextGen Precision Health, Columbia, Missouri, United States
- Ohio State University Wexner Medical Center, Colombus, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Nerve and Muscle Center of Texas, Houston, Texas, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06106672 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.